Bristol Myers said KarXT’s efficacy was maintained through one year in an open-label extension, presenting the data Saturday at the Schizophrenia International Research Society congress. Additionally, more than 75% of patients who continued taking the drug for a year achieved a “clinically meaningful” result, BMS senior VP of global drug development Roland Chen told Endpoints News. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER